Your fact-checks will appear here
Clinical trials comparing the efficacy of ribociclib and other treatments in advanced breast cancer.
Published -focused economic models repeatedly find to be both cheaper and more effective than palbociclib in first‑line HR+/HER2− advanced breast cancer, with multiple analyses also estimating ribocic...
’s evidence base for improving progression‑free survival (PFS) is strong and consistent: randomized phase III trials demonstrated statistically significant PFS benefit versus endocrine therapy alone, ...
, as tested in the program, is the only CDK4/6 inhibitor with consistent, statistically significant overall survival (OS) advantages reported across multiple phase III trials (MONALEESA‑2, ‑3, and ‑7)...